A Retrospective Study of the Management of Vulvodynia

Total Page:16

File Type:pdf, Size:1020Kb

A Retrospective Study of the Management of Vulvodynia www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.1.48 Sexual Dysfunction A Retrospective Study of the Management of Vulvodynia Yongseok Jeon, Youngjun Kim, Bosun Shim, Hana Yoon, Youngyo Park, Bongsuk Shim, Woosik Jeong, Donghyun Lee Department of Urology, Ewha Womans University School of Medicine, Seoul, Korea Purpose: Vulvodynia is characterized by chronic vulvar pain caused by sexual inter- Article History: course and often results in female sexual dysfunction. Because the causes of vulvodynia received 11 June, 2012 10 September, 2012 are not clear, many patients do not receive optimal treatment. Recently, gabapentin accepted and botulinum toxin A have both been shown to be effective treatments for vulvodynia. In this study, we retrospectively analyzed the clinical outcomes of botulinum toxin A and gabapentin treatment for chronic pain in women with this condition. Materials and Methods: Seventy-three women with vulvar pain were administered ei- ther gabapentin (n=62) or botulinum toxin A (n=11) injections. Effectiveness was meas- ured by use of a visual analogue scale (VAS). We analyzed the treatment method, treat- ment duration, success of treatment, and side effects or adverse reactions. Results: Pain levels in both groups significantly decreased after treatment. In the gaba- pentin group, the VAS score decreased from 8.6 before treatment to 3.2 after treatment (p<0.001). The VAS score in the botulinum toxin A group was reduced from 8.1 to 2.5 (p<0.001). Side effects for both therapies were few and subsided with treatment with general antibiotics and nonsteroidal antiinflammatory drugs. Conclusions: Gabapentin and botulinum toxin A are safe and effective treatments for vulvodynia. This condition can cause sexual dysfunction and affect quality of life. Corresponding Author: Hana Yoon However, with proper management, satisfactory outcomes for women with vulvodynia Department of Urology, Ewha Womans can be achieved. University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Keywords: Dyspareunia; Gabapentin; Type A botulinum toxins; Vulvodynia Seoul 158-710, Korea TEL: +82-2-2650-5157 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, FAX: +82-2-2654-3682 distribution, and reproduction in any medium, provided the original work is properly cited. E-mail: [email protected] INTRODUCTION ent areas of the vulva at different times, and it may be con- stant or occur only every once in a while. Vulvar vestibulitis Vulvodynia is a condition in women that is characterized syndrome is specifically characterized by pain in the vesti- by chronic vulvar pain. It may be present constantly, inter- bule and usually occurs in premenopausal women. In this mittently, or only with intromission during sexual inter- condition, pain occurs with vaginal entry by the penis or course. The term vulvodynia was originally coined by a tampon [1,2]. McKay [1], and it has been adopted by the International Patients with vulvodynia usually describe their pain as Society for the Study of Vulvar Disease Task Force to de- a chronic burning in the vulvovestibular area that typically scribe any vulvar pain [2]. There are no standardized clas- lasts more than 3 months. Before a diagnosis of vulvodynia sifications for vulvodynia largely because it is a multi- is made, other vulvovaginal problems should be ruled out factorial condition in which certain subsets coexist within [3,4]. Vulvodynia not only causes pain, but often leads to others. Generalized vulvodynia, or essential vulvodynia, sexual dysfunction, including arousal and orgasmic diffi- usually occurs in postmenopausal or perimenopausal culty [3,4]. For many women, it reduces overall personal women and is exhibited by diffuse, unremitting, and burn- health and quality of life. ing pain that is not cyclic [1-4]. This pain may occur in differ- The etiology of vulvodynia is not clear, and because of Korean Journal of Urology Ⓒ The Korean Urological Association, 2013 48 Korean J Urol 2013;54:48-52 A Retrospective Study of the Management of Vulvodynia 49 FIG. 1. The process of pain mapping and intralesional botulinum toxin A injection. (A) Using the Q-tip test, all painful areas were checked for intensity and localization. (B) Pain was scored by use of a visual analogue scale and mapped. (C) Botulinum toxin A was injected on the basis of the pain map (20 IU in each site, up to a maximal total dose of 100 IU). this, many patients do not receive optimal treatment. The formed on all 164 vulvar pain patients. Patients with ab- most common type of vulvodynia is vulvar vestibulitis syn- normal test results suggesting definitive infection, benign drome, which usually has an acute onset [5]. Vulvodynia tumor, or painful bladder syndrome were excluded, result- is generally associated with vaginitis, changes in sexual ac- ing in 73 patients with a diagnosis of vulvodynia of un- tivity, and a history of medical procedures on the vulva such known etiology. as cryotherapy or laser treatment (after which it often be- Using the Q-tip test, a cotton-tip was used to confirm pain comes a chronic problem). With vulvodynia in general, vul- in the vulvovestibular area and to measure its intensity var pain is variable in intensity, from mild to disabling. and localization (Fig. 1A, B). The patient’s objective pain Patients may feel burning, stinging, rawness, aching, sore- intensity was evaluated by use of a visual analogue scale ness, or throbbing that occurs in the vulva, labia, or vagina. (VAS) and was scored from 0 to 10. All pain characteristics A large proportion of patients attend multiple medical con- were self-recorded by the patient on a questionnaire. sultations before receiving a diagnosis, and no single treat- Patient data were analyzed according to treatment (either ment or combination of treatments have been shown to con- botulinum toxin A injection or gabapentin oral medi- sistently improve the symptoms. Recently, gabapentin a cation), treatment response, treatment duration, side ef- γ-aminobutyric acid (GABA) analogue anticonvulsant and fects, and pre- and posttreatment changes in VAS score. botulinum toxin A have been shown to be effective in treat- The method of vulvodynia treatment was selected accord- ing vulvodynia [3,6]. In this study, we performed a retro- ing to patient preference or response to previous treat- spective analysis of the clinical characteristics and the out- ment. Gabapentin was prescribed to the patients who pre- comes of these 2 drugs in the treatment of patients with ferred to take oral medication, with an initial dose of 300 vulvodynia. mg per day that was flexibly increased depending on response. Gabapentin administration was intended for at MATERIALS AND METHODS least 2 months, although the actual duration depended on patient willingness and response. This study was conducted by use of data from 73 patients Intralesional injection of botulinum toxin A (Botox, presenting with sexual dysfunction and vulvodynia out of Allegran Inc., Irvine, CA, USA) was used for patients who 164 total women with vulvar pain who visited our clinic preferred an injectable treatment and for those experienc- from 2002 to 2010. We reviewed the patients’ medical his- ing no pain relief from gabapentin oral treatment after tories and noted the type of drugs administered for pain more than 3 months. For treatment with botulinum toxin treatment and the duration of treatment. We also per- A, the entire vulvovestibular pain area was mapped with formed physical examinations, including a vaginal exami- a Q-tip. The drug was injected into the submucosal layer nation and vulvovaginal pain mapping with a cotton tip, at each painful area, after the pain in that area was re- to determine the location and degree of pain and to rule out confirmed (Fig. 1B, C). The dose of botulinum toxin A at other treatable causes of vulvar pain, such as infections of each injection site was 20 IU, and the total number of in- the vagina or uterus and genitourinary benign or malig- jection sites was limited to 5. The minimum total dose was nant tumors. Vulvodynia was diagnosed if the patient had 40 IU and the maximum dose was 100 IU. Two weeks after no other causes of vulvar pain that occurred either only dur- the injection, a telephone interview was conducted to check ing sexual activity or constantly. To rule out other painful, for any adverse reactions. If significant pain persisted at treatable, vulvar diseases, the patients’ previous and cur- any area of the vulvar vestibule at the 4-week follow-up, rent medical histories and medications were reviewed and additional injections were administered by use of the same urinalysis, urine culture with sensitivity test, papanico- method. After the second round of injections, no further laou test smears, and basic hematological tests were per- treatments were administered. Side effects, adverse re- Korean J Urol 2013;54:48-52 50 Jeon et al TABLE 1. Patient ages and treatment characteristics Characteristic Gabapentin Botulinum toxin A No. of patients 62 11 Age (y), mean±SD (range) 45.7±9.0 (31–65) 39.9±9.5 (25–55) Treatment duration (mo) 2.3±1.8 (0.5–6) NA Follow-up, 12.7 (6–24) Dose, mean (range) 329.03 mg/d (300–900 mg/d) 59.1 IU (40–100 IU; median, 50 IU) Side effect Nausea (6.5%, 4/62) Temporary pain on injection site (18.2%, 2/11) Drowsy (9.7%, 6/62) SD, standard deviation. actions, and treatment outcomes were assessed at 4 and 8 weeks after the initial injections. Every 2 months after the final round of injections, change in pain level and total dose received were recorded. All procedures were performed in an outpatient clinic with informed consent.
Recommended publications
  • The Leucoplakic Vulva: Premalignant Determinants C
    Henry Ford Hospital Medical Journal Volume 11 | Number 3 Article 3 9-1963 The Leucoplakic Vulva: Premalignant Determinants C. Paul Hodgkinson Roy B. P. Patton M. A. Ayers Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Hodgkinson, C. Paul; Patton, Roy B. P.; and Ayers, M. A. (1963) "The Leucoplakic Vulva: Premalignant Determinants," Henry Ford Hospital Medical Bulletin : Vol. 11 : No. 3 , 279-287. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol11/iss3/3 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 11, September, 1963 THE LEUCOPLAKIC VULVA Premalignant Determinants C. PAUL HODGKINSON, M.D.,* ROY B. P. PATTON, M.D., AND M. A. AYERS, M.D.* IN A PAPER proposing to discuss the leucoplakic vulva and any predisposing ten­ dency it may have to the development of squamous cell carcinoma, the term "pre­ malignant" has presumptuous connotations. This is presumptuous because it implies that more is known about cancer and its mode of development than can be supported by facts. What happens in the cell prior to the stage of carcinoma-in-situ is a burning and unsolved question in cancer research. How to detect and appraise the parameters of malignant potential is the essence of meaning connoted by the word "premalignant".
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • Localised Provoked Vestibulodynia (Vulvodynia): Assessment and Management
    FOCUS Localised provoked vestibulodynia (vulvodynia): assessment and management Helen Henzell, Karen Berzins Background hronic vulvar pain (pain lasting more than 3–6 months, but often years) is common. It is estimated to affect 4–8% of Vulvodynia is a chronic vulvar pain condition. Localised C women at any one time and 10–20% in their lifetime.1–3 provoked vestibulodynia (LPV) is the most common subset Little attention has been paid to the teaching of this condition of vulvodynia, the hallmark symptom being pain on vaginal so medical practitioners may not recognise the symptoms, and penetration. Young women are predominantly affected. LPV diagnosis is often delayed.2 Community awareness is low, but is a hidden condition that often results in distress and shame, increasing with media attention. Women can be confused by the is frequently unrecognised, and women usually see a number symptoms and not know how to discuss vulvar pain. The onus is of health professionals before being diagnosed, which adds to on medical practitioners to enquire about vulvar pain, particularly their distress and confusion. pain with sex, when taking a sexual or reproductive health history. Objective Vulvodynia The aim of this article is to inform health providers about the Vulvodynia is defined by the International Society for the Study assessment and management of LPV. of Vulvovaginal Disease (ISSVD) as ‘chronic vulvar discomfort, most often described as burning pain, occurring in the absence Discussion of relevant findings or a specific, clinically identifiable, neurologic 4 Diagnosis is based on history. Examination is used to support disorder’. It is diagnosed when other causes of vulvar pain have the diagnosis.
    [Show full text]
  • Effect of Educational Program on Vulvitis Prevention Among Nursing Students
    American Journal of Nursing Science 2018; 7(6): 254-267 http://www.sciencepublishinggroup.com/j/ajns doi: 10.11648/j.ajns.20180706.19 ISSN: 2328-5745 (Print); ISSN: 2328-5753 (Online) Effect of Educational Program on Vulvitis Prevention Among Nursing Students Somaya Ouda Abd EL-Menim 1, Huda Abdalla Moursi 2, Ahlam Elahmady Mohamed Sarhan 2 1Obstetric and Woman Health Nursing, Faculty of Nursing, Benha University, Benha, Egypt 2Community Health Nursing, Benha University, Benha, Egypt Email address: To cite this article: Somaya Ouda Abd EL-Menim, Huda Abdalla Moursi, Ahlam Elahmady Mohamed Sarhan. Effect of Educational Program on Vulvitis Prevention among Nursing Students. American Journal of Nursing Science . Vol. 7, No. 6, 2018, pp. 254-267. doi: 10.11648/j.ajns.20180706.19 Received : November 7, 2018; Accepted : November 23, 2018; Published : January 2, 2019 Abstract: The aim of this study was to evaluate the effect of educational program on vulvitis prevention among nursing students Research design: A quasi-experimental design was utilized. Setting: This study was conducted at Faculty of Nursing, Benha University. Sample: convenient sample included two hundred and fifty nursing students female all enrolled in first academic years. Tools of data collection1) a structured interviewing sheet to collect data about socio-demographic characteristics, menstrual and gynecological history and knowledge of nursing students regarding vulvitis 2) reported practices assessment 3) modified likert scale for students' attitude regarding vulvitis. Results: there were general improvements regarding students' knowledge, attitude and practice regarding prevention of vulvitis with highly significant (P ≤ 0.001) difference after educational Program. The mother was the main sources of knowledge to students (60%).
    [Show full text]
  • Female Genital Tuberculosis: a Clinicopathological Study
    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Desai RM et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2780-2783 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20162665 Research Article Female genital tuberculosis: a clinicopathological study Rathnamala M. Desai*, Sunil Kumar, Usha Brindini Department of Obstetrics and Gynaecology, Sri Dharmasthala Manjunatheshwara College of Medical Sciences and Hospital, Dharwad, Karnataka, India Received: 21 June 2016 Accepted: 09 July 2016 *Correspondence: Dr. Rathnamala M. Desai, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: The aim of this study was to describe the various clinical presentations of female genital tuberculosis and study the different methods of diagnosis and treatment. Methods: A study of all cases of female genital tuberculosis diagnosed in the last five years was done. Results: Female genital tuberculosis was diagnosed in 25 cases over a period of five years. Majority of the women (60%) were in the younger age group. Most of the women (60%) presented with infertility. Twelve (48%) women had primary infertility and 3 (12%) had secondary infertility. Nine (36%) women had secondary amenorrhea. Five (20%) women complained of abdominal pain. Thirteen (52%) women who underwent diagnostic hysterolaparoscopy as a part of evaluation for infertility were diagnosed to have genital tuberculosis.
    [Show full text]
  • An Overview of Vulvovaginal Atrophy‑Related Sexual Dysfunction in Postmenopausal Women
    Review Article An Overview of Vulvovaginal Atrophy‑Related Sexual Dysfunction in Postmenopausal Women Tochukwu Christopher Okeke, Cyril Chukwuma Tochukwu Ezenyeaku1, Lawrence Chigbata Ikeako1, Polycarp Uchenna Agu Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital (UNTH), Enugu, 1Anambra State University Teaching Hospital, Awka, Nigeria ABSTRACT Menopause and the climacteric period are associated with adverse risk factors for the development of vulvovaginal atrophy‑ related sexual dysfunction. Sexual dysfunction is a common problem in postmenopausal women, often underdiagnosed, inadequately treated, frequently overlooked, and most often impairing the quality of life of these women. To provide clinicians with current information on vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. This study is a literature review on vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. Relevant publications were identified through a search of PubMed and Medline, selected references, journals, and textbooks on this topic, and were included in the review. The prevalence of female sexual dysfunction increases with age. It is a common multidimensional problem for postmenopausal women that alter the physiological, biochemical, psychological, and sociocultural environment of a woman. Menopause‑related sexual dysfunction may not be reversible without therapy. Estrogen therapy is the most effective option and is the current standard of care for vulvovaginal atrophy‑related sexual dysfunction in postmenopausal women. Sexual dysfunction is a common multidimensional problem for postmenopausal women and often impairs the quality of life of these women. Estrogen preparations are the most effective treatment. Selective estrogen receptor modulators, vaginal dehydroepiandrostenedione, vaginal testosterone, and tissue‑selective estrogen complexes are promising therapies, but further studies are required to confirm their role, efficacy, and safety.
    [Show full text]
  • The Older Woman with Vulvar Itching and Burning Disclosures Old Adage
    Disclosures The Older Woman with Vulvar Mark Spitzer, MD Itching and Burning Merck: Advisory Board, Speakers Bureau Mark Spitzer, MD QiagenQiagen:: Speakers Bureau Medical Director SABK: Stock ownership Center for Colposcopy Elsevier: Book Editor Lake Success, NY Old Adage Does this story sound familiar? A 62 year old woman complaining of vulvovaginal itching and without a discharge self treatstreats with OTC miconazole.miconazole. If the only tool in your tool Two weeks later the itching has improved slightly but now chest is a hammer, pretty she is burning. She sees her doctor who records in the chart that she is soon everyyggthing begins to complaining of itching/burning and tells her that she has a look like a nail. yeast infection and gives her teraconazole cream. The cream is cooling while she is using it but the burning persists If the only diagnoses you are aware of She calls her doctor but speaks only to the receptionist. She that cause vulvar symptoms are Candida, tells the receptionist that her yeast infection is not better yet. The doctor (who is busy), never gets on the phone but Trichomonas, BV and atrophy those are instructs the receptionist to call in another prescription for teraconazole but also for thrthreeee doses of oral fluconazole the only diagnoses you will make. and to tell the patient that it is a tough infection. A month later the patient is still not feeling well. She is using cold compresses on her vulva to help her sleep at night. She makes an appointment. The doctor tests for BV.
    [Show full text]
  • Diagnosing and Managing Vulvar Disease
    Diagnosing and Managing Vulvar Disease John J. Willems, M.D. FRCSC, FACOG Chairman, Department of Obstetrics & Gynecology Scripps Clinic La Jolla, California Objectives: IdentifyIdentify thethe majormajor formsforms ofof vulvarvulvar pathologypathology DescribeDescribe thethe appropriateappropriate setupsetup forfor vulvarvulvar biopsybiopsy DescribeDescribe thethe mostmost appropriateappropriate managementmanagement forfor commonlycommonly seenseen vulvarvulvar conditionsconditions Faculty Disclosure Unlabeled Product Company Nature of Affiliation Usage Warner Chilcott Speakers Bureau None ClassificationClassification ofof VulvarVulvar DiseaseDisease byby ClinicalClinical CharacteristicCharacteristic • Red lesions • White lesions • Dark lesions •Ulcers • Small tumors • Large tumors RedRed LesionsLesions • Candida •Tinea • Reactive vulvitis • Seborrheic dermatitis • Psoriasis • Vulvar vestibulitis • Paget’s disease Candidal vulvitis Superficial grayish-white film is often present Thick film of candida gives pseudo-ulcerative appearance. Acute vulvitis from coital trauma Contact irritation from synthetic fabrics Nomenclature SubtypesSubtypes ofof VulvodyniaVulvodynia:: VulvarVulvar VestibulitisVestibulitis SyndromeSyndrome (VVS)(VVS) alsoalso knownknown asas:: • Vestibulodynia • localized vulvar dysesthesia DysestheticDysesthetic VulvodyniaVulvodynia alsoalso knownknown asas:: • “essential” vulvodynia • generalized vulvar dysesthesia Dysesthesia Unpleasant,Unpleasant, abnormalabnormal sensationsensation examplesexamples include:include:
    [Show full text]
  • Comparative Study of Tubal Patency by Hysterosalpingography, Transvaginal Sonosalpingography and Laparoscopy
    J. Anuradha, K. Aruna Kumari, A. Sujatha. Comparative study of tubal patency by hysterosalpingography, transvaginal sonosalpingography and laparoscopy. IAIM, 2016; 3(9): 126-133. Original Research Article Comparative study of tubal patency by hysterosalpingography, transvaginal sonosalpingography and laparoscopy J. Anuradha1*, K. ArunaKumari1, A. Sujatha1 1Assistant Professor, Department of Obstetrics and Gynaecology, Modern Government Maternity Hospital, Osmania Medical College, Hyderabad, India *Corresponding author email: [email protected] International Archives of Integrated Medicine, Vol. 3, Issue 9, September, 2016. Copy right © 2016, IAIM, All Rights Reserved. Available online at http://iaimjournal.com/ ISSN: 2394-0026 (P) ISSN: 2394-0034 (O) Received on: 20-08-2016 Accepted on: 30-08-2016 Source of support: Nil Conflict of interest: None declared. How to cite this article: J. Anuradha, K. Arunakumari, A. Sujatha. Comparative study of tubal patency by hysterosalpingography, transvaginal sonosalpingography and laparoscopy. IAIM, 2016; 3(9): 126-133. Abstract Background: Infertility is a global issue in reproductive health. In many cultures the ability to have children is important sign of an individual's worth. Aim and objective: To compare hysterosalpingography, transvaginal sonosalpingography and laparoscopic chromotubation for evaluation of tubal factor in infertility. Materials and methods: This consisted of 50 infertile women with either primary or secondary infertility. Including investigations for other factors, tubal factor was evaluated by hysterosalpingography, transvaginal sonosalpingography and laparoscopic chromotubation (in one or two cycles). Results: The results of 50 cases of Infertility for Tubal patency by sonosalpingography, HSG, laparoscopy. 36 cases were of primary infertility and 14 cases of secondary infertility. Mean duration of primary and secondary infertility were 5.79 ± 3.19 and 5.97 ± 3.36 years respectively.
    [Show full text]
  • Commonly Used ICD-10 Codes in Reproductive Healthcare
    FREQUENTLY USED CODES Commonly Used ICD-10 Codes in Reproductive Healthcare Female Reproductive Healthcare Breast Conditions Infertility Uterus N60.(01/02) Solitary cyst of breast (R/L) N97.0 Infertility-anovulation C54.1 Cancer of endometrium N60.(11/12) Fibrocystic change (R/L) E23.0 Hypopituarism C54.2 Cancer of myometrium N61 Mastitis, NOS N97.1 Infertility-tubal origin C54.3 Cancer of fundus uteri N64.0 Fissure and fistula of nipple N97.2 Infertility-uterine origin C54.9 Cancer of corpus uteri, unspec. N64.3 Galactorrhea N97.8 Infertility-cervical origin D25.9 Uterine myoma N64.4 Mastodynia N97.9 Female infertility, NOS N84.0 Polyp of corpus uteri N63 Lump or mass in breast N84.8 Polyp of other parts of fem genital N64.51 Induration of breast Menopause N84.9 Polyptract of fem. genital tract, unspec. N64.53 Retraction of nipple N92.4 Perimenopausal menorrhagia N85.00 Endometrial hyperplasia N64.59 Other signs/ symptoms in breast N95.0 Postmenopausal bleeding N85.4 Malposition of uterus N64.53 Retraction of nipple N95.1 Menopausal syndrome N85.6 Asherman’s syndrome O91.23 Mastitis, postpartum, unspec. N95.2 Atrophic vaginitis N85.7 Hematometra R92.8 Abnormal mammogram N95.8 Symptoms w artificial menopause N85.9 Disorder of uterus, NOS N95.9 Menopausal disorder NOS Cervix Urinary Tract C53.0 Endocervical cancer Ovary and Adnexa N30. 10 Interstitial cystitis w/o hematuria C53.1 Exocervical cancer C56.1 Malignant neoplasm of right ovary N30.11 Interstitial cystitis w/ hematuria C53.9 Cervical cancer, NOS C56.2 Malignant neoplasm of left
    [Show full text]
  • Lecture 21 Women's Reproductive Infectious Diseases And
    Lecture 21 Women’s Reproductive Infectious Diseases and Genitourinary Infections Elwood VULVOVAGINITIS: TRICHOMONIASIS: INFECTIOUS Protozoan• Trichomoniasis OVERVIEW: RISK FACTORS: Bacterial • Bacterial vaginosis (BV) • Protozoan! • Sexual contact with a confirmed or • Syphilis • Anaerobic parasitic flagellated suspected case • Gonorrhea protozoal infection • Unprotected sex with a resident of • Chlamydia • Most common non-viral STI an area with high burden and/or Viral • HSV • 3.1% reproductive-aged women high risk of antimicrobial resistance • HPV • 180 million infectious annually • History of previous infection Fungal • Yeast • Not reportable • History of other STIs, including HIV NON- Dermatosis• Lichen sclerosis • Sex workers & their sexual partners INFECTIOUS • Eczema • Contact dermatitis SYMPTOMS: • Sexually active youth < 25 yrs old • Atopic dermatitis FEMALES: • Street-involved youth and other • Psoriasis • Asymptomatic homeless populations • Bechet’s • Abdominal pain, dysuria • Individuals who have sex with Malignancy• Vulvar intraepithelial neoplasia • Vulvitis, vaginitis, pruritus, multiple partners • Vaginal intraepithelial neoplasia dyspareunia • Profuse discharge; frothy TESTING: yellow/green CORE PRINCIPLES: • Antigen • Wet mount – • Associated with infertility • Correct diagnosis • Culture must be received • PPROM, PTB, PP w/in 1 hr • Understand the organism you are targeting • NAAT endometritis • Correct medication, at the correct dose for the correct duration MALES: • “Treatment failure” • Asymptomatic TREATMENT: • Urethritis,
    [Show full text]
  • What's Going on Down There?
    What’s Going on Down There? Denise Rizzolo, PhD, PA-C Introduction • Vulvovaginitis is inflammation of the vulva and vaginal tissues. • Characterized by vaginal discharge and/or vulvar itching and irritation as well as possible vaginal odor. • Accounts for 10 million visits yearly in the US and is the most common gynecologic complaint in prepubertal girls. History- What should you ask? • Pruritus -General or just one spot • Soreness: stinging / burning / pain • Difficulty with sex • Lumps • Discharge • Partner’s have any symptoms • History of similar symptoms Physical Examination • Careful gynecologic exam • Inspection of discharge • Close examination of vulvovaginal area • Careful inspection of cervix • Look at perineum as well Physiologic Discharge • Responsible for 10 percent of cases of vaginal discharge. • Composed of vaginal squamous cells suspended in fluid medium. • Clinical characteristics: • clear to slightly cloudy • non-homogeneous • highly viscous • Changes throughout the month Normal Vaginal Discharge • Not associated with: • itching • burning • malodor • Normal increase in volume • ovulation • following coitus • after menses • during pregnancy The Big 3 •Three most common causes of vulvovaginitis include: • Bacterial Vaginosis • Vaginal candidiasis • Trichomonas Vaginalis •Others include: atrophic vaginitis, irritant vaginitis, and other STIs. Vaginal Candidiasis- Overview • Less common in postmenopausal women, unless taking estrogen. • 90% of yeast infections are secondary to Candida Albican (Most common). • Risk Factors
    [Show full text]